Loading…
Coffee consumption has been shown to decrease the risk of Hepatocellular Carcinoma (HCC) in patients with chronic liver disease
Hepatocellular Carcinoma (HCC) represents the fourth most common cause of cancer-related death.
Programmed cell death protein 1 (PD-1) / CD279, PD-L1 , and cytotoxic T lymphocyte associated protein 4 (CTLA-4) are proteins involved in the modulation of Immune responses , which are upregulated in hepatocellular carcinoma (HCC) tumor microenvironment (TME) .
Today, Herpes B virus / B virus (HBV) and Hepatitis C virus (HCV) (HCV) infections, as well as dietary aflatoxin and alcohol abuse, are significant risk factors for the occurrence of HCC. HBV and HCV accounting for 80% to 90% of all HCC cases.
Aberrant signaling of fibroblast growth factor 19 (FGF19) and its corresponding receptor, Fibroblast growth factor receptor 4 (FGFR4), are a driver of Hepatocellular Carcinoma (HCC) cell growth and survival.
The peripheral Immune responses in Hepatocellular Carcinoma (HCC) influences the clinical course of the disease, response to therapies, and overall survival
Hepatocellular Carcinoma (HCC) accounts for 75–85% of all primary liver cancers. It is the most common type of liver cancer and is the second leading cause of cancer deaths worldwide. Hepatocellular Carcinoma (HCC) can be broadly divided as non-proliferative and proliferative, with the latter being associated with poor outcome. Around 30% of the non-proliferative HCC cases have mutations in the catenin beta-1 (ctnnb1 gene) gene that activates the beta-catenin signaling pathway
Hepatocellular Carcinoma (HCC) is usually diagnosed at the late stages, leading to the low accessibility of curative therapy and high mortality
Hepatocellular carcinoma (HCC) is a malignant liver tumor characterized by high molecular heterogeneity, which has hampered the development of effective targeted therapies severely.
The distribution of Hepatocellular Carcinoma (HCC) is related to the incidence of Chronic Hepatitis B (CHB) and other factors, such as alcoholism , Aflatoxin B1 ingestion, and obesity
Chronic liver inflammation is a well-known risk factor for Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for approximately 90% of cases.
Hepatocellular carcinoma appears frequently in patients with cirrhosis.
The proliferative variant of Hepatocellular Carcinoma (HCC) is more aggressive and associated with high serum level of alfa-fetoprotein (AFP), expression of progenitor cell phenotype, tumor protein 53 (TP53) mutations, and activation of transforming growth factor beta (TGF- beta ), hepatocyte growth factor receptor (MET), protein kinase B (AKT), and insulin-like growth factor (IGF) 2 pathways
Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer, which is the second leading cause of cancer related deaths globally and has an incidence of 850,000 new cases per year. About 80% of cases of Hepatocellular Carcinoma (HCC) are associated with the presence of liver cirrhosis, which represents the final stage of injury, inflammation, and compensatory hepatocellular proliferation
Based on mutational signatures, aristolochic acid and tobacco, among others, have been identified as likely pathogenetic cofactors in Hepatocellular Carcinoma (HCC)
Serum concentration of Alfa-1 Fetoprotein may be a marker for Hepatocellular Carcinoma (HCC), but there is no good discrimination between neoplastic and non-neoplastic liver diseases
see also:
Hepatocarcinogenesis
Liver cancer
Mucosal-Associated Invariant T (MAIT) Cells